Business Context and Reporting Period
This Form 8-K Current Report, dated May 22, 2026, details significant executive leadership changes at Immunic, Inc. (IMUX). The filing announces the appointment of Erik Lundgren as Chief Executive Officer (CEO), effective June 1, 2026, and the concurrent resignation of Dr. Daniel Vitt from the CEO role, effective the same date. Dr. Vitt will remain on the Board of Directors and retain responsibility for scientific strategy.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- New CEO Base Salary: $685,000 annually.
- Target Annual Bonus: Minimum 60% of base salary ($411,000).
- Signing Bonus: $250,000 cash, payable within one month of the effective date.
- Performance Bonus: $200,000 cash contingent on the success of the Phase 3 trial for relapsing multiple sclerosis and continued employment through March 31, 2027.
- Equity Grant: Option to purchase 1,000,000 shares of common stock, time-vested over four years (25% at one year, 75% monthly thereafter).
Material Changes Versus Prior Period
The primary material change is the transition of the CEO role from Dr. Daniel Vitt to Erik Lundgren. The filing explicitly states that Dr. Vitt's resignation was not the result of any disagreement with the Company regarding operations, policies, or practices. There are no reported changes to Dr. Vitt's compensation arrangements at this time.
Guidance, Outlook, and Risks
Outlook and Milestones: The new CEO's compensation includes a specific milestone tied to the Company's clinical pipeline: a $200,000 bonus if the pending Phase 3 trial for relapsing multiple sclerosis meets primary efficacy and safety goals, justifying a New Drug Application submission, and Mr. Lundgren remains employed through March 31, 2027.
Severance and Contingencies: The Employment Agreement outlines significant severance provisions:
- Standard Termination (No Cause/Good Reason): 12 months of base salary plus 100% of target bonus, full acceleration of unvested equity, and 12 months of COBRA.
- Clinical Trial Failure Event: If terminated due to a Clinical Trial Failure Event on or prior to March 31, 2027, severance increases to 34 months of base salary.
- Change of Control: Enhanced severance of 18 months of base salary, 150% of target bonus, full equity acceleration, and 18 months of COBRA.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 1,000,000 share option grant to Mr. Lundgren.
- Confirm the current status and timeline of the Phase 3 trial for relapsing multiple sclerosis to assess the likelihood of the $200,000 performance bonus.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Clinical Trial Failure Event."
- Monitor future filings for any changes to Dr. Vitt's role or compensation as he transitions to a Board-only position.